This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
Protection against reinfection with SARS-CoV-2 omicron BA.2.75* sublineage
Preprint
in English
| medRxiv
| ID: ppmedrxiv-22281606
ABSTRACT
The BA.2.75* sublineage of SARS-CoV-2 B.1.1.529 (omicron) variant escapes neutralizing antibodies. We estimated effectiveness of prior infection in preventing reinfection with BA.2.75* using a test-negative, case-control study design. Effectiveness of prior pre-omicron infection against BA.2.75* reinfection, irrespective of symptoms, was 6.0% (95% CI 1.5-10.4%). Effectiveness of prior BA.1/BA.2 infection was 49.9% (95% CI 47.6-52.1%) and of prior BA.4/BA.5 infection was 80.6% (95% CI 71.2-87.0). Effectiveness of prior pre-omicron infection followed by BA.1/BA.2 infection against BA.2.75* reinfection was 56.4% (95% CI 50.5-61.6). Effectiveness of prior pre-omicron infection followed by BA.4/BA.5 infection was 91.6% (95% CI 65.1-98.0). Analyses stratified by time since prior infection indicated waning of protection since prior infection. Analyses stratified by vaccination status indicated that protection from prior infection is higher among those vaccinated, particularly among those ...
cc_no
Full text:
Available
Collection:
Preprints
Database:
medRxiv
Type of study:
Observational study
Language:
English
Year:
2022
Document type:
Preprint